Artikel ; Online: Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.
2021 Band 20, Heft 1, Seite(n) 235
Abstract: Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, ... ...
Abstract | Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, controls blood glucose and results in significant body weight loss in patients with type 2 diabetes. Beyond these well-known effects, an interesting aspect of this drug is its antiatherogenic activity, which should be further explored in clinical practice. This paper reviews the evidence related to oral semaglutide decreasing cardiovascular risk in patients with type 2 diabetes, focusing on the drug's antiatherosclerotic properties. The glucagon-like peptide 1 analogue restores endothelial dysfunction, induces vasodilatation, and reduces plasma lipids. Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events. Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management. |
---|---|
Mesh-Begriff(e) | Administration, Oral ; Animals ; Atherosclerosis/diagnosis ; Atherosclerosis/drug therapy ; Atherosclerosis/mortality ; Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cause of Death ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/mortality ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptides/administration & dosage ; Glucagon-Like Peptides/adverse effects ; Glycemic Control/adverse effects ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Incretins/administration & dosage ; Incretins/adverse effects ; Risk Assessment ; Risk Factors ; Treatment Outcome |
Chemische Substanzen | Biomarkers ; Blood Glucose ; GLP1R protein, human ; Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Incretins ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8) |
Sprache | Englisch |
Erscheinungsdatum | 2021-12-15 |
Erscheinungsland | England |
Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 2093769-6 |
ISSN | 1475-2840 ; 1475-2840 |
ISSN (online) | 1475-2840 |
ISSN | 1475-2840 |
DOI | 10.1186/s12933-021-01417-0 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.